Date: 2014-05-06
Type of information: Licensing agreement
Compound: MIF (Macrophage Migration Inhibitory Factor) inhibitors
Company: Debiopharm (Switzerland) Yale University (USA - CT)
Therapeutic area: Autoimmune diseases - Inflammatory diseases
Type agreement: R&D licensing
Action mechanism:
Disease:
Details: * On May 6, 2014, Debiopharm, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, has announced it has signed a new license and research agreement with Yale University, regarding the discovery of MIF inhibitors for treatment of autoimmune and inflammatory diseases. This joint effort will enable the discovery and development of potential oral first-in-class compounds that inhibit Macrophage Migration Inhibitory Factor (MIF), a key regulatory cytokine that has been linked genetically to the pathogenesis of several autoimmune and inflammatory diseases. Yale researchers Richard Bucala, MD, PhD, Professor of Medicine, Epidemiology and Pathology, and William L. Jorgensen, PhD, Sterling Professor of Chemistry and Director of the Division of Physical Sciences and Engineering, are leading the Yale scientific team designing small molecule antagonists to block inflammation in patients.
Financial terms:
Latest news:
